CN102210835B - 治疗冠心病的中药 - Google Patents
治疗冠心病的中药 Download PDFInfo
- Publication number
- CN102210835B CN102210835B CN 201110155727 CN201110155727A CN102210835B CN 102210835 B CN102210835 B CN 102210835B CN 201110155727 CN201110155727 CN 201110155727 CN 201110155727 A CN201110155727 A CN 201110155727A CN 102210835 B CN102210835 B CN 102210835B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- medicine
- blood
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 54
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 claims abstract description 18
- 241000005787 Cistanche Species 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 18
- 241000208340 Araliaceae Species 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 8
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 2
- 241001530126 Scrophularia Species 0.000 claims description 2
- 238000005056 compaction Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 46
- 210000004369 blood Anatomy 0.000 abstract description 42
- 210000003734 kidney Anatomy 0.000 abstract description 31
- 210000002216 heart Anatomy 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 22
- 239000009636 Huang Qi Substances 0.000 abstract description 17
- 210000004185 liver Anatomy 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 210000004204 blood vessel Anatomy 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 5
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 206010047163 Vasospasm Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000015271 coagulation Effects 0.000 abstract description 2
- 238000005345 coagulation Methods 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 230000003907 kidney function Effects 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 241001127714 Amomum Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000000513 Santalum album Species 0.000 abstract 1
- 235000008632 Santalum album Nutrition 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000008753 endothelial function Effects 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 abstract 1
- 231100000915 pathological change Toxicity 0.000 abstract 1
- 230000036285 pathological change Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 22
- 230000017531 blood circulation Effects 0.000 description 18
- 235000009508 confectionery Nutrition 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 14
- 229940126678 chinese medicines Drugs 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 9
- 206010010774 Constipation Diseases 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000008454 Hyperhidrosis Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- SJSOFNCYXJUNBT-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 239000009798 Shen-Fu Substances 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940039750 aconitine Drugs 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XUHJBXVYNBQQBD-UHFFFAOYSA-N mesaconitine Natural products COC1CC(O)C2(COC)CN(C)C3C(C(C45)(OC(C)=O)C(O)C6OC)C(OC)C2C31C4CC6(O)C5OC(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-UHFFFAOYSA-N 0.000 description 2
- XUHJBXVYNBQQBD-GQPWXMLZSA-N molport-002-525-145 Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H]6[C@@H](OC)[C@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H]4N(C)C[C@@]6([C@@H](C[C@@H]5OC)O)COC)C(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-GQPWXMLZSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- BDCURAWBZJMFIK-OGVVJMRYSA-N (1S,2R,3R,4S,5S,6S,8S,9S,10R,13S,16S,17R)-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-4,8-diol Chemical compound O[C@@H]1[C@H]2[C@@H]3[C@@]4([C@@H]5C6)[C@@H](OC)CC[C@@]5(COC)CN(CC)[C@@H]4[C@H]6[C@@]2(O)C[C@H](OC)[C@H]1C3 BDCURAWBZJMFIK-OGVVJMRYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- HTBWBWWADZJXID-TXEJJXNPSA-N Wuweizisu C Chemical compound COC1=C2C=3C(OC)=C4OCOC4=CC=3C[C@H](C)[C@H](C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-TXEJJXNPSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- JEJFTTRHGBKKEI-KBPBESRZSA-N dimethylgomisin J Natural products C1[C@H](C)[C@@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-KBPBESRZSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- HTBWBWWADZJXID-UHFFFAOYSA-N gamma-schisandrin Natural products COC1=C2C=3C(OC)=C4OCOC4=CC=3CC(C)C(C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-UHFFFAOYSA-N 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- BDCURAWBZJMFIK-XFFYPZHLSA-N talatisamine Natural products CCN1C[C@@]2(COC)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](O)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14 BDCURAWBZJMFIK-XFFYPZHLSA-N 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗冠心病的中药。其是由熟地、山茱萸、肉苁蓉、炮附子、人参、麦冬、桂枝、当归、黄芪、丹参、檀香、川芎、玄参、生地、山楂、银花、砂仁等植物中草药为原料制成。本发明药物用于治疗冠心病,具固本去标、复正除邪之功效,其是以调理肾脏功能为治疗的中心环节,同时注重肾、心、肝、脾等脏腑的机能协调,使肾阴得滋,下元得温、气血得补、淤血得解、热毒可清,不仅可以降脂抗凝、降低血液粘稠度,溶解血栓,还可以改善血管内皮功能,解除血管痉挛,抗动脉硬化,稳定易损斑块;对血液、血管病变具有双重治疗作用,可有效地治疗心血管系统疾病。
Description
技术领域
本发明涉及一种治疗冠心病的药物,具体涉及一种以植物中草药为原料制成的治疗冠心病的中药。
背景技术
冠心病是冠状动脉粥样硬化性心脏病的简称,是指供给心脏营养物质的血管--冠状动脉发生严重粥样硬化或痉挛,使冠状动脉狭窄或堵塞,以及血栓形成造成的管腔闭塞,导致心肌缺血缺氧或梗塞的一种心脏病,亦称缺血性心脏病。冠心病是动脉粥样硬化导致器官病变的最常见类型,是危害中老年人健康的常见病,并呈现年轻化倾向。冠脉变窄的原因在于:血液中的血脂长期过高、胆固醇日积月累地沉淀在冠状动脉管腔的内膜上,形成地图样斑块,使本来光滑的内膜变的粗糙,柔软的管壁变得僵硬,在此基础上,破裂的血小板也凝聚粘附上去,于是就像河道被淤泥堵塞一样,使冠脉管腔变窄,甚至完全闭塞。冠脉的不畅甚至完全闭塞,造成心肌供血不好,心肌得不到血液的营养而坏死称为心肌梗死,这是冠心病最严重的表现。一旦心肌大面积梗死,又不能快速消除的话,那么人的生命也就结束了。现代医学在这种理念的指导下,对心脏病的治疗手段大体分为两类:一是使用药物包括扩张血管类药物和溶栓溶脂类药物;二是支架、搭桥手术。在冠心病的治疗中,介入手术和搭桥手术都属于有创治疗,同时手术后并发症严重影响患者的身体健康。这些方法在对心脏病患者的治疗特别是在抢救性阶段有重要意义是行之有效的。但是却不能从源头上解决血管内脂质等垃圾的再次沉淀形成新的斑块,致使血管重新变窄、堵塞,心肌供血不畅老病复发的问题。
近年来上市的治疗冠心病心绞痛的中药新药中多以活血化瘀,理气止痛疗法为主,如地奥心血康、丹参口服液、复方丹参胶囊、心通口服液、补心气口服液、滋心阴口服液、益气口服液及专利文献CN 1244372C中公开的治疗心血管疾病中药制剂等等,而临床研究表明:心肾虚弱为年高之人常见的病因病机,单施祛瘀活血唯恐伤正,而若以“滋肾养心”禹于之中,既防伤正之弊,又可增强心肾功能,更有助于活血化瘀,行气止痛。
发明内容
本发明要解决的技术问题是提供一种符合中医辨证论治之观点,实现育阴温阳的治疗冠心病的中药。
为解决上述技术问题,本发明采用的技术方案是:
一种治疗冠心病的中药,由下述重量份的原药制成的药剂:
熟地25~50份、山茱萸10~25份、肉苁蓉15~30份、炮附子5~20份、人参5~15份、麦冬15~25份、五味子2.5~10份、桂枝5~15份、甘草5~10份、当归10~25份、黄芪15~50份、丹参15~50份、檀香1.5~5份、砂仁5~10份、川芎5~15份、山楂10~20份、银花15~25份、玄参15~25份、生地15~50份。
所述药物为口服液剂、散剂、片剂、胶囊剂中的任意一种。
所述口服液剂的制备方法为:将总原料按药:水之容量比为1:2~4加水浸泡至少0.5小时,再加适量水煎煮0.5~2小时,虑去药渣后无菌保藏或无菌灌装即可。
所述药剂的制备方法为:将总原料按药:水之容量比为1:2~10加水浸泡至少0.5小时,再加适量水煎煮0.5~2小时,滤去药渣,在负压、低温的条件下将澄清的中药浸出液浓缩至波密度为80%以上,通过喷粉设备制成干粉(喷口的温度≤100℃),再向干粉中添加填充剂后制成片剂或胶囊剂。
所述药剂的制备方法为:将各原药研磨成细粉后按比例混合,并过100~200目筛,即为散剂,或将粉末压制成片剂,或将粉末装入胶囊制成胶囊剂。
本发明具有积极有益的效果:
1.辩证用药与组方原理
冠心病属胸痹、心悸、真心痛范畴,临床表现为心动悸、脉结代、心绞痛、疲倦无力、胸闷气短或烦躁汗出等症候。关于该病的发病机理,发明人认为,人生活自然中,外有六淫(风、寒、暑、湿、燥、火),内有七情(喜、怒、忧、思、悲、惊、恐);人体内在环境各部脏腑之间,以及内在环境和外界环境只有在相互协调,相互平衡的状态下,才能维持正常的生理活动,表现为健康的体征;若人体内部脏腑之间失去平衡、气机失调,就会使正气受损,正气不足,则外邪内侵,疾病生成,即所谓“正气存内,邪不可干”、“邪之所凑、其气必虚”;多年的临床医疗实践中发现心血管病六种证侯(心血瘀阻、寒凝心脉、痰浊内阻、心肾阴虚、心肾阳虚,心气虚弱)中,心肾阴虚、心肾阳虚、心气虚弱者居多,这是因为肾阴虚、肾阴不能上济于心,则心阳上亢,心不得安;肾阴虚,肝失滋养,又导致肝阳上亢,肝风内动,心肝俱亢,日久化火,致使血枯粘稠。肾阳虚,肾阳不能上温养于心,则心阳不旺;肾阳不足,又可使脾阳不振,运化无力,形成心脾两虚;心气虚弱,鼓动血液运行的力度减小,速度减慢,流量减少。在这种血液粘稠、流速缓慢的情况下,血液中的脂质、胆固醇等物质极易沉积在血管内壁,使血管内腔变窄,堵塞血管内腔,造成心肌缺血形成胸痹,而全身血管也必然会受损,尤其是脑血管受损后,易致中风。据此,在治疗和预防心血管疾病中,应以肾脏为中心环节,注重调理肾心肝脾肺各脏,使之协调,共生共荣。
冠心病病机复杂,既有正虚的一面,又有邪实的一面。正虚的一面包括心肾阴虚、心肾阳虚、心气虚弱;邪实的一面包括气滞血瘀、热毒入营。鉴于冠心病病机复杂,虚实互见之证,非单方所可治。根据“奇之不去则偶之,一方不去则复之”的原则,发明人多年来采用滋补肾阴、温煦元阳、益气养血、活血化瘀、清解血毒、理气止痛,诸法复合成本发明所述药物,疗效颇佳。
本发明药物撷取地黄饮子、生脉散、桂枝甘草汤、参附汤、当归补血汤、丹参饮、四妙勇安汤、增液汤等诸方之长,并结合长期临床经验加减化裁而成。本发明药物用甘温的熟地与酸温的山茱萸相配补益肾阴;肉苁蓉温壮肾阳,配伍辛热的附子,以温养下元,上药四味可奏阴阳并补之功;生脉散,以其人参甘温益气生津以补肺,肺气旺则诸脏之气皆旺,麦冬甘寒养阴补水之源,五味子酸温敛肺生津,全方可益气生津,敛阴止汗;参附汤益气强心壮阳、温通血脉,常作心梗、心衰之急救方;桂枝、甘草温通心阳,专治心阳虚之心悸;当归补血汤,以黄芪补脾肺之气,以资生化,当归养血通脉,奏补气生血之功;方中丹参饮,丹参活血化瘀,止痛而不伤气血,檀香、砂仁温中行气止痛,此药三味,药性平和、气血并治,既可化瘀行气止痛,又是治疗寒疾阻滞、胸阳不振之胸痹心痛的良方,更配川芎、山楂活血化瘀,止痛效果更佳;银花、玄参暗合当归、甘草即为四妙勇安汤,可清热解毒、活血止痛,再配丹参活心血、养心散淤,医治心痛更见其功。
临床诊断为冠心的病患者中,兼患糖尿病者不少,而糖尿病反过来又使冠心病加重,在治疗冠心病的同时,必须重视糖尿病的控制,方中黄芪、生地、玄参、丹参,现代医学研究都具有很好的降血糖作用。再者,冠心病患者特别是老年冠心病患者兼患有便秘者不少,便秘对一般人来说不算什么大病,但对冠心病患者来说可谓心腹大患,由于便秘使排便困难,在排便用力时,心脏压力负荷增大,容易诱发心梗猝死,为顾及这一问题,方中生地、玄参、麦冬构成增液汤,功在生津润燥、润肠通便。
各味原料药的药理药效:
熟地,甘,微温。归肝、肾经。补血养阴,填精益髓。熟地黄能显著抑制肝脏出血性坏死灶及单纯性坏死;对高脂食物引起的高脂血症,脂肪肝及大鼠内毒素引起的肝静脉出血症,均有抑制血栓形成的作用;对纤溶酶原的激活作用,是抗血栓形成的作用机制。
山茱萸,酸、涩,微温。归肝、肾经。补益肝肾,涩精固脱。用于眩晕耳鸣,腰膝酸痛,阳痿遗精,遗尿尿频,崩漏带下,大汗虚脱。内热消渴。山茱萸能增强机体的抗应激能力,提高小鼠耐缺氧、抗疲劳能力,增强记忆力。山茱萸能提高红细胞中SOD活性,对抗脂质过氧化。其醇提物还有降血脂作用,可降低血清甘油三酯、胆固醇的含量,抗动脉硬化。
肉苁蓉,归经甘、咸,温。归肾、大肠经。补肾阳,益精血,润肠通便。《本草经疏》: 滋肾补精血之要药,甘能除热补中,酸能入肝,咸能滋肾,肾肝为阴,阴气滋长,则五脏之劳热自退,阴茎中寒热痛自愈。
炮附子,辛,大热,有毒。入心、脾、肾经。回阳救逆,温里逐寒,温经止痛。含多种生物碱:次乌头碱(Hypa-conitine)、乌头碱(Aconitine)、新乌头碱(Mesaconitine)、塔拉胺(Talatisamine)、川乌碱甲和川乌碱乙等。
人参,性平、味甘、微苦,微温。归脾、肺经。大补元气,复脉固脱,补脾益肺,生津止渴,安神益智。人参对心肌有保护作用。人参皂甙能降低小鼠在严重缺氧情况下大脑和心肌的乳酸含量,能恢复缺氧时心肌cAMP/cGMP 比值,并具有保护心肌毛细血管内皮细胞及减轻线粒体损伤的作用。
麦冬,甘、微苦,微寒。归心、肺、胃经。养阴生津,润肺清心。用于肺燥干咳。虚痨咳嗽,津伤口渴,心烦失眠,内 热消渴,肠燥便秘;咽白喉。麦冬可能使梗塞后心肌营养血流量增加,缺血缺氧的心肌细胞较快获得修复与保护,致使心肌cGMP和cAMP的释放减少,从而降低血浆中的含量,而使两者比值恢复平衡。
五味子,温;酸、甘;归肺、心、肾经。收敛固涩,益气生津,补肾宁心。五味子有扩血管作用。五味子素、五味子丙素、去氧五味子素等对于离体狗肠系膜动脉收缩均有抑制作用,能增加脉鼠离体心脏及麻醉狗冠脉血流量。五味子有利于组织细胞的氧气交换,能对心脏组织产生保护作用,还可平缓心跳频率和纾解高血压。
桂枝,辛、甘,温。归心、肺、膀胱经。发汗解肌,温通经脉,助阳化气,平冲降气。扩张血管,调节血液循环,使血液流向体表,加强麻黄发汗作用。
甘草,性平,味甘,归十二经。有解毒、祛痰、止痛、解痉以至抗癌等药理作用。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
当归,性温,昧甘、辛。归肝、心、脾经。补血活血,调经止痛,润肠通便。当归能改善体内高凝状态,调整血脂代谢,降低胆固醇。
黄芪,性甘,微温。归肺、脾、肝、肾经。有益气固表、敛汗固脱、托疮生肌、利水消肿之功效。黄芪能增强心肌收缩力,扩张冠脉,改善心肌血供和心肌代谢,提高超氧化物歧化酶活力,减低脂质过氧化物含量,从而减轻自由基造成的损伤。
丹参,苦,微寒。归心、肝经。活血调经,祛瘀止痛,凉血消痈,清心除烦,养血安神。丹参能活血化瘀,通络止痛,养血宁心,可增加冠心病血流量,改善心肌收缩力,而不增加心肌缺氧量,促进侧支循环及血流再分配。
檀香,辛,温。归脾、胃、心、肺经。行气温中,开胃止痛。用于寒凝气滞,胸痛,腹痛,胃痛食少;冠心病,心绞痛。
砂仁,味辛,性温。归脾经、胃经、肾经。《医林纂要》:润肾,补肝,补命门,和脾胃,开郁结。
川芎,辛,温。归肝、胆、心包经。活血行气,祛风止痛。用于安抚神经,正头风头痛,症瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。川芎能扩张平滑肌,改善微循环,并有抗凝、抗聚集作用,并通过扩张末梢血管而降压。
山楂,味酸、甘,性微温。归脾、胃、肝经。开胃消食、化滞消积、活血散瘀、化痰行气。用于肉食滞积、症瘕积聚、腹胀痞满、瘀阻腹痛、痰饮、泄泻、肠风下血等。山楂能显著降低血清胆固醇及甘油三酯,有效防治动脉粥样硬化;山楂还能通过增强心肌收缩力、增加心输出量、扩张冠状动脉血管、增加冠脉血流量、降低心肌耗氧量等起到强心和预防心绞痛的作用。此外,山楂中的总黄酮有扩张血管和持久降压的作用。
银花,甘、寒。归肺、胃经。功效:清热解毒。具有降血脂作用。
玄参,味甘、苦、咸; 性微寒。归肺,胃,肾经。温邪入营,内陷心包,温毒发斑,热病伤阴、舌绛烦渴、津伤便秘、骨蒸劳嗽、目赤、咽痛、瘰疬、白喉、痈肿疮毒。
生地,甘,寒。归心、肝、肾经。清热凉血,养阴,生津。用于热病舌绛烦渴,阴虚内热,骨蒸劳热,内热消渴,吐血,衄血,发斑发疹。
2.功能与主治
本发明药物用于治疗冠心病,具固本去标、复正除邪之功效,其是以调理肾脏功能为治疗的中心环节,同时注重肾、心、肝、脾等脏腑的机能协调,使肾阴得滋,下元得温、气血得补、淤血得解、热毒可清,不仅可以降脂抗凝、降低血液粘稠度,溶解血栓,还可以改善血管内皮功能,解除血管痉挛,抗动脉硬化,稳定易损斑块;对血液、血管病变具有双重治疗作用,可有效地治疗心血管系统疾病。
3.病证诊断与疗效标准
依据国家中医药管理局1994年6月28日发布的《中医病证诊断疗效标准》进行病证诊断及疗效标准的判断。
发明人近二十年来先后接待了数千名应诊者,其中保留有完整的病历档案记录的1129人,其中男性748人,女性381人。年龄在40~55岁者175人,56~65岁者597人,66岁以上者357人。1129位应诊者中,病程最短者80多天,最长者达15年。
对应诊者口服“护肾保心汤”水煎剂,每日一剂,一个月为一疗程,一般患者一个疗程自觉症状明显改善,大多数患者三至四个疗程达到治愈或显效。服药期间详细观察记录患者治疗前后的临床表现,如发现不良反应,采取相应处理。观察期间其他药物一律停止。临床疗效分析见表1,从表中可知本方剂临床总有效率达96.14%,并且在治疗期间未发现本药剂具有明显的毒副作用。
表1 中医证型与临床疗效分析
具体实施方式
实施例1 一种治疗冠心病的中药,由下述原药制成:
熟地35g、山茱萸20g、肉苁蓉25g、炮附子15g、人参10g、麦冬20g、五味子6g、桂枝10g、甘草8g、当归18g、黄芪35g、丹参40g、檀香3.5g、砂仁7g、川芎10g、山楂15g、银花20g、玄参20g、生地35g。
以上即为一付药剂的原料构成(批量生产时,各组分按比例扩大),将其按药:水之容量比为1:2加水浸泡1.5小时,再加适量水煎煮1小时,虑去药渣,获药液150 mL,灭菌后密封灌装即可。分早、中、晚三次服,每次50mL,一个月为一个疗程。
实施例2 一种治疗冠心病的中药,由下述原药制成:
熟地25g、山茱萸10g、肉苁蓉15g、炮附子5g、人参5g、麦冬15g、五味子2.5g、桂枝5g、甘草5g、当归10g、黄芪15g、丹参15g、檀香1.5g、砂仁5g、川芎5g、山楂10g、银花15g、玄参15g、生地15g。
以上即为一付散剂的原料构成,将当归、山楂等含水多的原药冷冻干燥再粉碎,含水量低的各原药直接粉碎成细粉,并过150目筛,即制得散剂。每天早、中、晚服用3次,每次服原生药细粉6~12g,一个月为一个疗程。
实施例3 一种治疗冠心病的中药,由下述原药制成:
熟地50g、山茱萸25g、肉苁蓉30g、炮附子20g、人参15g、麦冬25g、五味子10g、桂枝15g、甘草10g、当归25g、黄芪50g、丹参50g、檀香5g、砂仁10g、川芎15g、山楂20g、银花25g、玄参25g、生地50g。
以上即为一付中成药的原料构成。制备时,将总原料按药:水之容量比为1:3加水浸泡至少1h,再加适量水煎煮2h,滤去药渣,在负压、低温的条件下将澄清的中药浸出液浓缩至波密度为75%以上,通过喷粉设备制成干粉(喷口的温度≤100℃),再向干粉中添加适量药用淀粉后压制成片剂(以上为常规的中药制备技术)。每天服用3次(早、中、晚),每次服4~6片(相当于原生药8~12g),一个月为一个疗程。
实施例4 一种治疗冠心病的中药,由下述原药制成:
熟地40g、山茱萸15g、肉苁蓉20g、炮附子10g、人参8g、麦冬18g、五味子7g、桂枝12g、甘草6g、当归22g、黄芪40g、丹参35g、檀香2g、砂仁8g、川芎12g、山楂17g、银花18g、玄参22g、生地40g。制备及服用方法同实施例1。
实施例5 一种治疗冠心病的中药,由下述原药制成:
熟地30g、山茱萸15g、肉苁蓉16g、炮附子8g、人参6g、麦冬16g、五味子3g、桂枝7g、甘草8g、当归12g、黄芪17g、丹参16g、檀香3g、砂仁6g、川芎6g、山楂12g、银花16g、玄参16g、生地17g。制备及服用方法同实施例1。
实施例6 一种治疗冠心病的中药,由下述原药制成:
熟地45g、山茱萸24g、肉苁蓉28g、炮附子18g、人参14g、麦冬24g、五味子9g、桂枝13g、甘草9g、当归23g、黄芪45g、丹参48g、檀香4.5g、砂仁9g、川芎14g、山楂18g、银花24g、玄参24g、生地45g。制备及服用方法同实施例1。
实施例7 一种治疗冠心病的中药,由下述原药制成:
熟地30g、山茱萸22g、肉苁蓉18g、炮附子20g、人参7g、麦冬23g、五味子3g、桂枝15g、甘草7g、当归24g、黄芪18g、丹参45g、檀香1.5g、砂仁8g、川芎6g、山楂12g、银花24g、玄参16g、生地42g。制备及服用方法同实施例2。
实施例8 一种治疗冠心病的中药,由下述原药制成:
熟地48g、山茱萸11g、肉苁蓉28g、炮附子6g、人参13g、麦冬16g、五味子9g、桂枝5g、甘草9g、当归12g、黄芪48g、丹参16g、檀香4g、砂仁6g、川芎14g、山楂18g、银花16g、玄参24g、生地18g。制备及服用方法同实施例3。
实施例9 一种治疗冠心病的中药,由下述原药制成:
熟地26g、山茱萸12g、肉苁蓉29g、炮附子9g、人参12g、麦冬19g、五味子8g、桂枝8g、甘草8g、当归23g、黄芪38g、丹参46g、檀香2.5g、砂仁6g、川芎7g、山楂13g、银花22g、玄参19g、生地28g。制备及服用方法同实施例3。
实施例10 一种治疗冠心病的中药,由下述原药制成:
熟地38g、山茱萸18g、肉苁蓉27g、炮附子11g、人参11g、麦冬17g、五味子5.5g、桂枝7g、甘草7g、当归11g、黄芪32g、丹参42g、檀香4.5g、砂仁7.5g、川芎7g、山楂12g、银花17g、玄参18g、生地25g。制备及服用方法同实施例1。
实施例11 一种治疗冠心病的中药,由下述原药制成:
熟地32g、山茱萸14g、肉苁蓉22g、炮附子14g、人参7g、麦冬19g、五味子3g、桂枝9g、甘草7g、当归13g、黄芪28g、丹参26g、檀香2g、砂仁6g、川芎7g、山楂13g、银花17g、玄参16g、生地28g。制备及服用方法同实施例1。
实施例12 一种治疗冠心病的中药,由下述原药制成:
熟地47g、山茱萸23g、肉苁蓉27g、炮附子17g、人参13g、麦冬22g、五味子8g、桂枝13g、甘草8g、当归23g、黄芪43g、丹参44g、檀香4g、砂仁8g、川芎14g、山楂19g、银花24g、玄参22g、生地41g。制备及服用方法同实施例1。
下面仅列举近几年的一些具体病例说明:
病例1 赵世法,男,55岁,河南省新蔡县涧头乡赵塘村农民,1987年患冠心病,多次去省城多家大医院诊治未见有明显疗效,于1989年6月前来发明人处就诊,给服实施例1所述的治疗冠心病的中药,连续两个疗程后(一个月为一疗程,下同),症状消除,追访两年无复发。
病例2 马金龙,男,41岁,河南省新蔡县化庄集人,2000年10月诊断出患冠心病,于2001年4月经人介绍来发明人处就诊,给服实施例2所述的治疗冠心病的中药,连服近两个疗程后,症状完全消除,追访2年无复发。
病例3 徐国华,男,60岁,河南省新蔡县孙召乡机关干部,2005年8月诊断出患冠心病,多方求医,花钱无数,均无明显疗效,于2008年2月前来发明处就诊,给服实施例3所述的治疗冠心病的中药,连服两个多疗程后,症状完全消除,追访2无复发。
病例4 赵世琳,女,63岁,河南省新蔡县某机关退休干部,2005年12月25日突发心梗,前来发明人处就诊,给服实施例4所述治疗冠心病的中药两个半疗程后,经复查,心梗症状完全消除,追访两年无复发。
病例5 徐国华,男,69岁,河南省新蔡县栎城乡陈楼村人,2004年3月诊断出患冠心病,几年内四处求医诊治,未能见效,耗资巨大,2006年6月慕名前来发明人处求医治疗,给服实施例5所述的治疗冠心病的中药,连服三个疗程后,自觉症状消除,追访3年无复发。
病例6 代兢山,男,1927年生,河南省新蔡县某中学教师,30多岁时检查诊断出患有冠心病,虽四处求治,仍经常发作,患病历史长达几十年。2005年6月慕名前来发明人处就诊,给服实施例6所述治疗冠心病的中药,8个疗程后,复查病症消除,五年来再未发作。
病例7 代良辰,男,1933年生,河南省新蔡县文化系统离休职工,多年前诊断出患冠心病,多方医治,未见有疗效。2000年5月慕名前来发明人处就诊,给服实施例8所述的治疗冠心病的中药4个疗程后,症状消除,十年来未复发。
Claims (5)
1.一种治疗冠心病的中药,其特征在于,它是由下述重量份的原药制成:
熟地25~50份、山茱萸10~25份、肉苁蓉15~30份、炮附子5~20份、人参5~15份、麦冬15~25份、五味子2.5~10份、桂枝5~15份、甘草5~10份、当归10~25份、黄芪15~50份、丹参15~50份、檀香1.5~5份、砂仁5~10份、川芎5~15份、山楂10~20份、银花15~25份、玄参15~25份、生地15~50份。
2.根据权利要求1所述的治疗冠心病的中药,其特征在于,所述药物为口服液剂、散剂、片剂、胶囊剂中的任意一种。
3.根据权利要求2所述的治疗冠心病的中药,其特征在于,所述口服液剂的制备方法为:将总原料按药:水之容量比为1:2~4加水浸泡至少0.5小时,再加适量水煎煮0.5~2小时后虑去药渣即可。
4.根据权利要求2所述的治疗冠心病的中药,其特征在于,所述片剂或胶囊剂的制备方法为:将总原料按药:水之容量比为1:2~10加水浸泡至少0.5小时,再加适量水煎煮0.5~2小时,滤去药渣,在负压、低温的条件下将澄清的中药浸出液浓缩至波密度为80%以上,通过喷粉设备制成干粉,喷口的温度≤100℃,再向干粉中添加填充剂后制成片剂或胶囊剂。
5.根据权利要求2所述的治疗冠心病的中药,其特征在于,所述散剂、片剂或胶囊剂的制备方法为:将各原药研磨成细粉后按比例混合,并过100~200目筛,即为散剂,或将粉末压制成片剂,或将粉末装入胶囊制成胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110155727 CN102210835B (zh) | 2011-06-10 | 2011-06-10 | 治疗冠心病的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110155727 CN102210835B (zh) | 2011-06-10 | 2011-06-10 | 治疗冠心病的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102210835A CN102210835A (zh) | 2011-10-12 |
CN102210835B true CN102210835B (zh) | 2013-08-21 |
Family
ID=44742519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110155727 Expired - Fee Related CN102210835B (zh) | 2011-06-10 | 2011-06-10 | 治疗冠心病的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102210835B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102600255A (zh) * | 2012-03-29 | 2012-07-25 | 周柳池 | 冠心舒通胶囊 |
CN103919910B (zh) * | 2014-04-29 | 2015-09-30 | 山东省立医院 | 一种治疗冠心病的药物 |
CN104189714A (zh) * | 2014-09-20 | 2014-12-10 | 田丽华 | 一种治疗冠心病的中药胶囊 |
CN105311538A (zh) * | 2015-11-21 | 2016-02-10 | 戴淑娟 | 治疗心脏供血不足的中药及制作方法 |
CN115337348B (zh) * | 2021-08-05 | 2023-10-24 | 中国中医药科技发展中心(国家中医药管理局人才交流中心) | 一种治疗热结血脉的中药组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1136444A (zh) * | 1995-05-22 | 1996-11-27 | 王希亚 | 心康宝 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1176814A (zh) * | 1997-06-26 | 1998-03-25 | 李静 | 预防和治疗脑血管病的口服液 |
CN1305483C (zh) * | 2005-11-08 | 2007-03-21 | 吴家录 | 一种调节心衰的中药药物 |
CN100427130C (zh) * | 2006-12-04 | 2008-10-22 | 杨梅青 | 治疗心血管病的药物 |
-
2011
- 2011-06-10 CN CN 201110155727 patent/CN102210835B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1136444A (zh) * | 1995-05-22 | 1996-11-27 | 王希亚 | 心康宝 |
Also Published As
Publication number | Publication date |
---|---|
CN102210835A (zh) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101507765B (zh) | 一种用于治疗心脑血管疾病及其后遗症的药物及其制备方法 | |
CN101716242B (zh) | 一种治疗心脑血管疾病的中药 | |
CN104606513A (zh) | 一种治疗心脑血管疾病的中药及其制备方法 | |
CN102210835B (zh) | 治疗冠心病的中药 | |
CN104758806A (zh) | 一种治疗冠心病的煎膏剂及其制备方法 | |
CN101524469A (zh) | 一种治疗充血性心力衰竭的中药复方制剂及其制备方法 | |
CN103919910B (zh) | 一种治疗冠心病的药物 | |
CN101524470B (zh) | 一种防治心血管疾病支架再狭窄的中药制剂及制备方法 | |
CN101337017A (zh) | 一种治疗冠心病的药物 | |
CN103610936B (zh) | 一种治疗冠心病的中药制剂及制备方法 | |
CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 | |
CN104825956A (zh) | 防治中风、康复筋骨关节的药 | |
CN104189714A (zh) | 一种治疗冠心病的中药胶囊 | |
CN103142897B (zh) | 一种贲门失弛缓症术后用药 | |
CN103212044B (zh) | 一种治疗心血管疾病的中药组合物 | |
CN102406769B (zh) | 一种治疗高血压、高血脂、动脉硬化、冠心病的中药制剂及其制备方法 | |
CN105169078A (zh) | 一种治疗糖尿病的中药组合物 | |
CN105687962A (zh) | 治疗冠状动脉粥样硬化的冲剂及制备方法 | |
CN104324134A (zh) | 一种改善微循环的中药组合物及其制备方法 | |
CN103142898B (zh) | 一种贲门失弛缓症术后用药的制备方法 | |
CN101244209B (zh) | 预防或治疗心脑血管疾病的药物 | |
CN106606726A (zh) | 一种冠心病治疗药剂及制作方法 | |
CN105125694A (zh) | 一种快速降压膏及其制作方法 | |
CN104547930A (zh) | 脾虚湿热甲型黄疸肝炎清热利湿药剂及制备方法 | |
CN104547999A (zh) | 产后发汗用油 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 |
|
CF01 | Termination of patent right due to non-payment of annual fee |